Source: Health Canada shortage reports · Updated Jul 9, 2026
Some Ambrisentan products are in shortage in Canada (2 of 8 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer.
A medication used to treat pulmonary arterial hypertension.
Products affected
2 / 8
In shortage since
Aug 7, 2025
Reports on file
13
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
JAMP AMBRISENTAN
5MG · TABLET · JAMP PHARMA CORPORATION
DIN 02521938 · since Aug 7, 2025, est. end Jun 30, 2026 · Disruption of the manufacture of the drug.
Active shortage
JAMP AMBRISENTAN
10MG · TABLET · JAMP PHARMA CORPORATION
DIN 02521946 · since Aug 7, 2025, est. end Jun 30, 2026 · Disruption of the manufacture of the drug.
Avoided
VOLIBRIS
5MG · TABLET · GLAXOSMITHKLINE INC
DIN 02307065 · ended Nov 12, 2025 · Disruption of the manufacture of the drug.
Avoided
VOLIBRIS
10MG · TABLET · GLAXOSMITHKLINE INC
DIN 02307073 · ended Nov 12, 2025 · Disruption of the manufacture of the drug.
Discontinued
SANDOZ AMBRISENTAN TABLETS
10MG · TABLET · SANDOZ CANADA INCORPORATED
DIN 02526883
Resolved
SANDOZ AMBRISENTAN TABLETS
10MG · TABLET · SANDOZ CANADA INCORPORATED
DIN 02526883 · ended Jul 2, 2025 · Disruption of the manufacture of the drug.
Resolved
SANDOZ AMBRISENTAN TABLETS
5MG · TABLET · SANDOZ CANADA INCORPORATED
DIN 02526875 · ended Jun 30, 2025 · Disruption of the manufacture of the drug.
Discontinued
SANDOZ AMBRISENTAN TABLETS
5MG · TABLET · SANDOZ CANADA INCORPORATED
DIN 02526875
Resolved
VOLIBRIS
10MG · TABLET · GLAXOSMITHKLINE INC
DIN 02307073 · ended Feb 24, 2025 · Disruption of the manufacture of the drug.
Resolved
SANDOZ AMBRISENTAN TABLETS
10MG · TABLET · SANDOZ CANADA INCORPORATED
DIN 02526883 · ended Apr 23, 2024 · Disruption of the manufacture of the drug.
Resolved
SANDOZ AMBRISENTAN TABLETS
5MG · TABLET · SANDOZ CANADA INCORPORATED
DIN 02526875 · ended Apr 23, 2024 · Requirements related to complying with good manufacturing practices.
Resolved
APO-AMBRISENTAN
10MG · TABLET · APOTEX INC
DIN 02475383 · ended Jun 11, 2021 · Disruption of the manufacture of the drug.
Showing 12 of 13 reports. All reports are on file with Health Canada.
What's happening
Ambrisentan is currently affected by 2 active shortage reports filed with Health Canada by JAMP PHARMA CORPORATION.
The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Ambrisentan is classified under “OTHER ANTIHYPERTENSIVES” (ATC C02KX).
Recent changes
No changes recorded yet.
Common questions
What is Ambrisentan used for?
A medication used to treat pulmonary arterial hypertension.
When will Ambrisentan be back in stock in Canada?
Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.
Why is Ambrisentan in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.